Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

The FDA approval was based on the pooled data from two pivotal studies: the EMERALD trial and NI-0501-06.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

Ogsiveo (nirogacestat) is approved by the Food and Drug Administration (FDA) for adults with progressing desmoid tumours requiring systemic treatment. The European Medicines Agency’s (EMA) Committee ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

German contract development and manufacturing organisation Vetter Pharma has commenced construction of a new $285m clinical manufacturing facility in Des Plaines in the US state of Illinois with a ...

Torrent has signed definitive agreements to acquire stake in JB Pharma at an equity valuation of Rs256.89bn ($3bn) on a fully ...

As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply ...

Brii Biosciences and Joincare Pharmaceutical have signed a licence and technology transfer agreement for BRII-693 for MDR/XDR infections.

By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the potential.